This study examines the 2020 NCCN Guidelines for Rectal Cancer, highlighting updates in diagnosis, treatment, and follow-up for localized and metastatic disease. The guidelines incorporate neoadjuvant therapy advancements and emerging biomarker-targeted therapies, reflecting a paradigm shift in colorectal cancer management. By integrating novel approaches, the guidelines aim to optimize patient outcomes and standardize care. This review analyzes the implications of these updates, providing insight into the evolving landscape of rectal cancer treatment and the role of precision medicine in improving therapeutic efficacy.